Nancy Van Osselaer
Dr Van Osselaer is an experienced global biopharmaceutical professional with over 25 years experience leading drug development projects at leading pharmaceutical companies. Nancy currently serves as an independent consultant for her company Why2What, which provides strategic implementation advice to biotech companies.
Nancy was previously Vice President Early Stage Development portfolio leader at Galapagos, where she was responsible for the strategy and development of early assets, including the cystic fibrosis program and various highly innovative assets in the immune-inflammation space. Before joining Galapagos, Nancy worked at UCB where she worked to identify better outcomes for neurology patients beyond the current treatment regimes.
Prior to this, Nancy spent over 17 years at Johnson and Johnson contributing to multiple registration files and participating in development review committees.
Nancy is a pharmacist by training and holds a PhD in pharmacology from the University of Antwerp, Belgium.